X0206 3 2019-06-27 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001214133 SCHELLER RICHARD H C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 1 1 0 0 See Remarks No securities beneficially owned. 0 D Common Units 0.00 Common Stock 6886 D Common Units 0.00 Common Stock 19318 D Management Incentive Units 0.00 Common Stock 59381 D Management Incentive Units 0.00 Common Stock 42100 D Management Incentive Units 0.00 Common Stock 35742 D Stock Option (right to buy) 17.00 2019-06-26 Common Stock 82665 D Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all outstanding units in BridgeBio Pharma LLC (the "LLC") will be exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer will be merged with and into the LLC, and shares of Common Stock will be allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it is liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 21, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of January 19, 2018, such that the shares shall be fully vested on January 19, 2023, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Chairman of Research and Development Exhibit 24.1 - Power of Attorney /s/ Ralph Scarborough, as attorney-in-fact 2019-06-27